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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by an irreversible airflow limitation in
response to inhalation of noxious stimuli, such as cigarette smoke. However, only 15–20 % smokers manifest COPD,
suggesting a role for genetic predisposition. Although genome-wide association studies have identified common
genetic variants that are associated with susceptibility to COPD, effect sizes of the identified variants are modest, as
is the total heritability accounted for by these variants. In this study, an extreme phenotype exome sequencing
study was combined with in vitro modeling to identify COPD candidate genes.
Results: We performed whole exome sequencing of 62 highly susceptible smokers and 30 exceptionally resistant
smokers to identify rare variants that may contribute to disease risk or resistance to COPD. This was a cross-sectional
case-control study without therapeutic intervention or longitudinal follow-up information. We identified candidate
genes based on rare variant analyses and evaluated exonic variants to pinpoint individual genes whose function was
computationally established to be significantly different between susceptible and resistant smokers. Top scoring
candidate genes from these analyses were further filtered by requiring that each gene be expressed in human
bronchial epithelial cells (HBECs). A total of 81 candidate genes were thus selected for in vitro functional testing
in cigarette smoke extract (CSE)-exposed HBECs. Using small interfering RNA (siRNA)-mediated gene silencing
experiments, we showed that silencing of several candidate genes augmented CSE-induced cytotoxicity in vitro.
Conclusions: Our integrative analysis through both genetic and functional approaches identified two candidate
genes (TACC2 and MYO1E) that augment cigarette smoke (CS)-induced cytotoxicity and, potentially, COPD
susceptibility.
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Background
Chronic obstructive pulmonary disease (COPD), charac-
terized by a permanent airflow limitation, is a growing
public health threat and a leading cause of disability and
mortality worldwide [1, 2]. Although cigarette smoking
is a major risk factor [3], evidence suggests that genetic
factors modulate smoking-induced COPD [4]. For
example, alpha1 antitrypsin deficiency (A1ATD), caused
by a homozygous missense mutation of SERPINA1 (PiZ;
Glu342Lys) or compound heterozygosity of the PiZ and
PiS variants, contributes to lung function decline among
smokers [5, 6]. However, A1ATD accounts for only 2–3 %
of COPD cases [7]. Genome-wide association study
(GWAS) and fine-mapping studies have revealed common
(>5 % minor allele frequency) single nucleotide polymor-
phisms (SNPs) that are associated with COPD in a num-
ber of candidate genes, including CHRNA3/5, FAM13A,
and HHIP [8–11]. However, the effect sizes for these asso-
ciated common variants are small relative to those of SER-
PINA1-mediated A1ATD and COPD. Sequencing studies
of COPD hold the promise of identifying rare variants
with large effects on disease susceptibility.
Recent developments in DNA sequencing technologies
have dramatically reduced the cost of acquiring genetic
data. In particular, whole exome sequencing (WES) has
become a valuable tool for studying both rare and com-
mon diseases [12]. WES allows interrogation of the entire
coding portion of the human genome at a fraction of the
cost of whole-genome sequencing. In a recent study, WES
led to the identification of a non-synonymous SNP in the
gene CCDC38 that was associated with resistance to
cigarette smoke (CS)-related airflow obstruction, assessed
by sequencing heavy smokers with normal lung function
[13]. Therefore, to identify potential causal variants for
both COPD and CS resistance, we conducted WES of 62
smokers with very advanced COPD and 30 resistant
smokers. We sought to sample from the extremes of the
phenotypic distribution, under the assumption that this
would enrich sampling of rare causal variants with large
effect sizes [14]. The COPD group was thus selected to
contain the youngest, lightest smoking, and most severely
diseased individuals from available cohorts; the resistant
group was selected to contain the oldest, heaviest smok-
ing, and healthiest individuals (i.e., no comorbidities) with
normal lung function. The primary analytical approach
was aimed at identifying rare variants (and the associated
genes) contributing to these two phenotypes. Additionally,
we employed approaches focusing on the collective impact
of multiple weakly deleterious variants (both common and
rare). Candidate genes were further filtered using gene ex-
pression analysis to retain a total of 81 genes, which were
functionally tested in CS-exposed, immortalized human
bronchial epithelial cells (HBECs) using a gene knock-
down approach (Fig. 1). This systematic multi-layered ap-
proach may help remove false-positives and prioritize true
COPD (or CS-induced damage resistance) genes. HBECs
were chosen as an in vitro screening model because air-
way epithelial cells are the primary target of CS exposure.
CS exposure induces inflammation, DNA damage, and
autophagy that causes lung epithelial cells to undergo vari-
ous cell fates, including cell death, cellular senescence,
and/or transformation [15]. Although there is no sine qua
non cellular phenotype of lung epithelial cells in COPD,
the lungs of patients with COPD exhibit a significant
Fig. 1 Identifying candidate COPD genes through genomic and functional approaches. WES in 62 highly susceptible smokers and 30 exceptionally
resistant smokers were conducted to identify exonic variants that may contribute to disease risk or resistance to CS. Top scoring candidate genes from
the rare variant and gene set analyses were further filtered by requiring that the gene be expressed in primary HBECs, and 81 candidate genes were
selected for in vitro functional testing in CSE-exposed HBECs. Using siRNA-mediated gene silencing experiments, we identified candidate genes whose
knockdown augmented CSE-induced cytotoxicity, protected CSE-induced cytotoxicity, or alone-reduced cell viability
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increase in apoptotic cells [16, 17]. We thus chose in vitro
cell viability as an endpoint.
Results
VAAST analysis
We performed WES on 62 susceptible smokers with
COPD and 30 resistant smokers with normal spirometries
in the absence of significant comorbidities (Table 1). All
individuals were of self-reported non-Hispanic white eth-
nicity. We used the Variant Annotation, Analysis, and
Search Tool (VAAST) program to prioritize candidate
genes (Additional file 1) [18, 19]. Given allele frequency
and amino acid substitution severity, VAAST prioritizes
genes based on their disease-causing likelihood. We per-
formed VAAST analysis under different settings, including
different modes of inheritance, penetrance models, and
individual sets. From the VAAST output, several hundred
genes had a p value <0.05 under each analysis set-up
(Table 2). We did not use a more stringent cutoff or a false
discovery ratio (FDR) correction for the p value because
these candidate genes would be further prioritized in the
downstream analyses and validated by an in vitro assay.
Some of the top-ranking candidate genes from the
VAAST analysis contain rare deleterious mutations in
multiple susceptible individuals. For example, the gene
TACC2 was ranked 6th with complete penetrance and
22nd with 5 % prevalence in our VAAST analysis of the
susceptible group under a recessive inheritance model.
One of the susceptible individuals carries a nonsense
stop-gain mutation (chr10: 123842508) in TACC2 (a glu-
tamine mutated to a stop codon). Six additional suscep-
tible individuals carry novel mutations at different
positions of this gene, making TACC2 a promising can-
didate. Using Sanger sequencing, we validated all non-
sense and non-synonymous TACC2 variants where the
DNA samples were available, for a total of seven variants
in eight COPD samples, including four novel variants
(Additional file 7: Table S1). The 100 % validation rate
for the seven variants suggests that the variant calls are
of high quality.
Gene functional deficit score-based TTest and FCBF
analysis
To determine the collective impact of all variants,
including common and weakly deleterious variants, a
gene functional deficit score was calculated for all genes.
Of our set of 15,594 variant-affected genes in at least
one individual in either the susceptible smokers or the
resistant smokers, 848 genes attained p values of <0.05
(TTest set); 194 genes attained a p value <0.01 for the t
test comparing resistant individuals to susceptible indi-
viduals (TTest tab in Additional file 2). However, none
of the p values were significant after Bonferroni correc-
tion for multiple comparisons. To account for lack of
variability and small numbers of samples in the score
distributions, we further reduced the reference gene set
by keeping only those affected in at least 10 individuals
in both resistant and susceptible cohorts (8877 genes
affected in at least 20 individuals). This reduction did
not produce any genes with significant corrected p
values either. This result suggests that either more
individuals are necessary for improved resolution of
the study or that the resistant and susceptible pheno-
types are the result of additive or epistatic interaction
of altered function of multiple genes.
Next, we performed fast correlation-based filter solu-
tion (FCBF) attribute analysis and the FCBF selection
resulted in a set of 368 relevant genes (FCBF set) (of
these, 59 attained an [average merit − standard error] > 0;
FCBF tab in Additional file 2). Of the entire set, 62 %
(229) and 38 % (139) of the genes had higher average
scores in susceptible and resistant individuals respectively
(FCBF tab in Additional file 2). The large proportion of
genes showing higher scores in resistant individuals sug-
gests that COPD resistance may be a separate variation-
conferred phenotype, as opposed to solely reflecting the
absence of COPD-predisposition variants.
To determine if the FCBF genes are often found
together in biological interaction and regulation net-
works, we used the induced network modules analysis
in ConsensusPathDB [20], an integrative database for
gene interaction networks. The vast majority of FCBF
genes (336 of 368, 91.3 %) were mappable in Consen-
susPathDB (FCBF tab in Additional file 2). The
induced network modules analysis connects FCBF
genes/proteins (seed network nodes) into modules
using knowledge of different types of interactions
(network edges) between these seeds and other inter-
mediate network nodes, such as other genes, chemical
ligands, and proteins. A single network is composed
of one module or several disconnected modules. In
our analysis, we considered binary interactions only,
including protein-protein interactions, genetic interac-
tions, biochemical reactions, and gene regulatory
interactions. The first step in the analysis induced
Table 1 Demographic data of resistant smokers and COPD
subjects
Resistant smokers COPD p value
Gender (M/F) 7/23 34/28 <0.01*
Age 65.7 ± 5.3 57.7 ± 7.0 <0.0001#
Pack year 62.2 ± 20.6 45.7 ± 19.0 0.0003#
FEV1/FVC% 76.9 ± 5.9 29.5 ± 9.5 <0.0001#
% predicted FEV 103.9 ± 11.4 25.8 ± 11.4 <0.0001#
% predicted DLCO N/A 32.8 ± 16.5 N/A
*Fisher exact test
#t test
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three modules containing 160 (44 % of our set of 368)
interacting seeds (Z-score of intermediate nodes ≥ 20; net-
work1 FCBF tab in Additional file 2). The largest module
contained 96 % (154) of the seeds and 50 intermediate
nodes; the remaining two modules contained a total of six
seeds and two intermediates. Removing low confidence
interactions (IntScore <0.5) [21] maintained 138 (38 %)
seeds (network2 FCBF tab in Additional file 2; one module
of 37 intermediate nodes and 126 seeds, plus five smaller
networks encompassing the remaining 12 seeds and 2 in-
termediates). Building a network of solely high-confidence
(IntScore >0.95) protein-protein and biochemical interac-
tions forms a module of 111 (30 %) connected seeds (net-
work 3 FCBF tab in Additional file 2; 24 intermediate
nodes, 96 seeds in a single network, plus six smaller
modules with 15 seeds and 3 intermediates). Finally,
leaving only high-confidence protein-protein interac-
tions retains 43 (12 %) interacting seeds (network 4
FCBF tab in Additional file 2; 12 intermediates and 20
seeds in a single module, plus nine smaller modules of
23 seeds and 7 intermediates, total). Eliminating all
intermediates resulted in a high-confidence module of 8-
seed proteins (network 5 FCBF tab in Additional file 2).
Mutagenesis of interacting proteins without a link to a
common phenotype is an unlikely event. Thus, these
results suggest that, in the absence of otherwise unifying
features of tested individuals, a disruption of an as yet
undescribed molecular pathway may be involved in gener-
ating the COPD phenotype.
Candidate gene filtering using RNA-Seq in vitro analysis
Both bronchial and alveolar epithelial cells are the primary
target of CS exposure. To determine the abundance of
gene expression in primary human bronchial epithelial
cells (pHBECs), we conducted RNA-Seq using pHBEC
cultures isolated from five nonsmoking donors. We found
that 96.2 % of all genes are expressed within a tenfold dif-
ference among the five donors. Therefore, we prioritized
the candidate genes expressing at an average fragments
per kilobase of transcript per million mapped reads
(FPKM) of 1.0 or more (50.4 % of 32,457 transcripts) in
pHBECs, assuming that transcripts with an FPKM value
below 1.0 have low expression [22] (Additional file 3).
Three sets of candidate genes were screened for their
expression levels: genes from the (1) VAAST analysis
(Additional file 1) and the (2) gene functional deficit score
analysis using the t test (TTest tab in Additional file 2)
and (3) FCBF (FCBF tab in Additional file 2). For the
VAAST analysis, we first filtered candidate genes using the
following criteria: (1) present in both dominant and reces-
sive analyses under the 5 % background allele frequency
setting (i.e., present in analyses 1 and 5 or in analyses 2
and 6 in Table 2) and (2) having a gene ranking <300 in at
least one of the analyses. These selection criteria resulted
in 363 candidate genes from VAAST analysis. For the
TTest and FCBF analyses, we included all candidate genes.
Among the three sets of candidate genes, 363, 498, and
199 genes have an average FPKM value larger than 1.0,
including 932 unique genes. To generate a set of candidate
genes for in vitro functional analysis, we further examined
the biological relevance of these candidate genes based on
current knowledge of COPD. In the end, we selected a
total of 81 of the highest scoring candidate genes for
siRNA screening from (1) VAAST analysis (n = 42) and (2)
FCBF and/or t test analysis (n = 45). Six genes overlapped
between the VAAST and FCBF or t test analyses
(Additional file 4). All variants with annotations within
the 81 candidate genes are listed in Additional file 5.
To confirm these genes are relevant to COPD, we per-
formed Gene Ontology (GO) term and pathway enrich-
ment analysis on the 81 candidate genes. Among the 81
genes, a number of GO terms showed significant enrich-
ment (Additional file 6). The top genes are associated
with cell death, which supports our hypothesis that the
COPD susceptible genes are associated with cell viability
and response to cigarette smoke extract (CSE) toxicity.
In addition, using the induced network modules analysis
in ConsensusPathDB, 48 out of the 81 genes are con-
nected in a network when allowing intermediate nodes,
supporting their involvement in a common pathway
Table 2 The number of candidate genes under different VAAST analysis categories
VAAST analysis category Analysis Candidate genes
Inheritance Parameters Samples
Dominant 5 % background allele frequency Resistant vs. susceptible background 1 534
Susceptible vs. resistant background 2 757
Complete penetrance Resistant vs. susceptible background 3 343
Susceptible vs. resistant background 4 366
Recessive 5 % background allele frequency Resistant vs. susceptible background 5 532
Susceptible vs. resistant background 6 759
Complete penetrance Resistant vs. susceptible background 7 195
Susceptible vs. resistant background 8 269
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(data not shown). Note that since the candidate genes
were selected from the computationally identified gene
set using expert knowledge, this enrichment in relevant
GO terms does not indicate discovery but rather con-
firms our findings.
siRNA screening in vitro analysis
To determine whether the selected candidate genes (n =
81) are important for cell survival against cigarette
smoke exposure, we examined the effects of 2 % CSE on
cell viability in cultured HBECs (HBEC2) in which the
individual gene expression had been suppressed using
siRNA (Additional file 4). According to the gene silencing-
CSE interaction analysis, we identified two candidate genes
whose gene silencing augmented CSE-induced cytotoxicity
(TACC2 and MYO1E) and one candidate gene whose gene
silencing protected against CSE-induced cytotoxicity
(SLC7A1) (Tables 3 and 4). Among the candidate genes,
suppression of TACC2 expression induced the most pro-
nounced effect of CSE on cell viability (Table 3 and Add-
itional file 4). We confirmed the effects of siRNA
transfection on CSE-induced cytotoxicity (Fig. 2a) and gene
silencing by RT-PCR (Fig. 2b). We also performed flow cy-
tometric analysis with Annexin V and propidum iodide
staining to characterize the CSE-induced cytotoxicity in
HBEC2 cells transfected with TACC2 siRNA. The percent-
age of early and late apoptotic cells in response to CSE was
significantly increased by TACC2 knockdown (52.2 ±
11.6 %) as compared to scrambled controls (8.1 ± 1.7 %)
(Fig. 2c). Furthermore, TACC2 knockdown activated
caspase-3 in CSE-exposed HBEC2 (Fig. 2d). These data
suggest that the effects of CSE on cytotoxicity of TACC2
knockdown cells may largely be due to apoptosis.
We also identified three candidate genes whose sup-
pression alone (in the absence of CSE) significantly
reduced cell viability (PLCH2, KIAA1919, and MRPS34)
(Table 5). These results demonstrate that WES can iden-
tify candidate genes whose gene silencing significantly
alters spontaneous or CSE-induced cytotoxicity.
Discussion
We conducted a WES study using an extreme phenotype
design (susceptible vs. resistant smokers) to prioritize
candidate genes that potentially modify COPD susceptibil-
ity. Among the prioritized candidate genes expressed in
pHBECs, we identified two genes (TACC2 and MYO1E)
that exhibited a strong interaction of gene (siRNA trans-
fection) with environment (CS exposure) on cytotoxicity
in vitro.
Missing heritability is a well-recognized phenomenon
in GWAS of complex phenotypes [23, 24]. Potential
explanations for missing heritability include epistatic
interactions (GxG) and gene-environment interactions
(GxE), as well as experimental limitations, e.g. discarding
informative variants due to stringent GWAS significance
thresholds and insufficient linkage disequilibrium be-
tween typed and “causal” variants. Rare disease-causing
variants may also be responsible for a substantial pro-
portion of the missing heritability [25–27].
To identify candidate genes from the WES dataset, we
used two complementary approaches that focused on
either rare variants with presumably large effect sizes
(VAAST analyses) or on multiple weakly deleterious var-
iants causing molecular function changes (gene func-
tional deficit score-based TTest and FCBF analyses). We
used these diverse approaches because the genetic model
for our phenotypes of interest is largely unknown. For
example, if COPD is caused by the accumulation of mul-
tiple mutations that weakly alter the function of several
genes in a certain molecular pathway, the VAAST
approach is unlikely to identify the underlying causes
and the gene deficit analysis is more appropriate. Unfor-
tunately, the hypothesis of multiple interacting muta-
tions giving rise to a phenotype is very challenging to
test with both in vitro and in vivo models, as simultan-
eous evaluation of multiple mutations is necessary.
Nevertheless, we expect that mapping these candidate
genes will identify crucial molecular pathways respon-
sible for the development of the resistance and COPD
phenotypes.
The current state of the art, as described in the scientific
literature, confirms some genes identified by our analysis:
of the complete set of FCBF genes, 32 were found by a
computational parsing of articles identified by the MeSH
term “pulmonary disease, chronic obstructive”—the expli-
cit term referring to COPD; another 20 genes were
Table 3 Top five candidate genes whose gene silencing
augmented CSE-induced cytotoxicity
Gene ID Interaction (AD/CB) Z-score p value BH FDR
1 TACC2* 0.196 −6.090 0.0000 0.0010
2 MYO1E* 0.614 −2.924 0.0017 0.0020
3 NPLOC4 0.727 −2.070 0.0192 0.0030
4 FUT2 0.763 −1.796 0.0363 0.0040
5 PEX26 0.797 −1.537 0.0622 0.0050
*p value < BH FDR
Table 4 Top five candidate genes whose gene silencing
protected against CSE-induced cytotoxicity
Gene ID Interaction (AD/CB) Z-score p value BH FDR
1 SLC7A1* 1.334 2.959 0.0015 0.0016
2 INO80 1.213 1.882 0.0300 0.0032
3 AXIN1 1.190 1.878 0.0302 0.0048
4 EREG 1.189 1.673 0.0471 0.0065
5 MAP3K10 1.177 1.519 0.0644 0.0081
*p value < BH FDR
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identified by searching for COPD related keywords
(chronic obstructive lung disease, chronic obstructive air-
way disease, chronic airflow limitation, chronic obstructive
respiratory disease, chronic bronchitis, COAD, COPD)
(FCBF tab in Additional file 2). These results suggest that
the selected gene set contains a substantial number of
known COPD genes and is possibly enriched in yet unde-
scribed COPD and/or COPD-resistance associated genes.
With this knowledge, we will be able to examine the role
of gene-gene interaction and weak functionally deleterious
mutations in the future as larger sample sizes for genetic
studies are acquired and more sophisticated genome-
editing technologies are employed in functional studies.
A total of 81 candidate COPD genes selected from our
analysis were functionally tested using an in vitro gene
knockdown model combined with exposure to CSE. We
chose the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide (MTT) assay as a measure of cell viabil-
ity because it is more sensitive in detecting CSE effects
(such as cell growth inhibition) than the trypan blue
exclusion or LDH release assay (unpublished data).
Fig. 2 Effects of TACC2 siRNA transfection on CSE-induced
cytotoxicity and TACC2 mRNA levels. a Forty-eight hours after
transfection with either siRNA targeting TACC2 (TACC2 siRNA) or
the scrambled siRNA (scrambled control) as control, HBEC2 cells were
incubated in the absence (no CSE) or presence of 2 % CSE (CSE) for
24 h. Cell viability was determined using the MTT assay at 24 h. Data
are expressed as mean ± SEM for three independent experiments with
triplicated samples (*p < 0.05; **p < 0.01). b Steady-state levels of TACC2
mRNA were measured by RT-PCR and presented as relative fold
difference compared with CDKN1B in HBEC2 cells after 48 h with either
TACC2 siRNA or scrambled control. Data are expressed as mean ± SEM
from two independent experiments with triplicated samples
(**p < 0.01). c HBEC2 cells were treated as in a. Cell death was analyzed
by Annexin V and propidium iodide (PI) staining 24 h after 2 % CSE
exposure. The percentage of Annexin V positive cells/total cell number
was expressed as percentage apoptosis. Data are expressed as mean ±
SEM for three independent experiments (**p < 0.01). Representative
flow cytometry data are shown. d HBEC2 cells were treated as in a.
Immunoblot analysis of active caspase-3 was performed 24 h after 2 %
CSE exposure. Immunoblotting data are representative of
three experiments
Table 5 Top five candidate genes whose gene silencing alone
reduced cell viability
Gene ID Ratio (C/A) Z-score p value BH FDR
1 PLCH2* 0.490 −3.359 0.00039 0.00109
2 KIAA1919* 0.492 −3.342 0.00041 0.00217
3 MRPS34* 0.528 −3.030 0.00122 0.00326
4 EPPK1 0.607 −2.365 0.00901 0.00435
5 NAT10 0.612 −2.281 0.01127 0.00544
*p value < BH FDR
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Notably, in addition to cigarette smoking, premature
growth of the lung is also thought to be a risk factor for
COPD [28]. Therefore, when analyzing the siRNA
screening data, we considered two experimental states:
(1) gene-environment interaction (both gene silencing
and CSE exposure) and (2) siRNA-induced cytotoxicity
(gene silencing alone). From the interaction analysis, we
identified two candidate genes (TACC2 and MYO1E)
whose knockdown increased CSE-induced cytotoxicity.
Both genes were identified in susceptible smokers.
TACC2 gene knockdown most dramatically augmented
CSE-induced cytotoxicity. TACC2, a member of the
transforming acidic coiled-coil-containing protein family,
is involved in the regulation of centrosome and micro-
tubule dynamics during cell cycling [29] but is not
necessary for cell growth and mouse fertility and devel-
opment [30]. The TACC2 functions suggest that it may
modulate both resistance (through a gain-of-function
mutation) and susceptibility (through a loss-of-function
mutation) to smoking-induced COPD. In fact, a recent
human study identified a common TACC2 variant as sig-
nificantly associated with the resistant smoker phenotype
[13]. MYO1E encodes a non-muscle class I myosin
involved in cytoskeleton dynamics; homozygous non-
synonymous SNPs in MYO1E are associated with familial
focal segmental glomerulosclerosis [31]. A recent in vitro
study demonstrated that genetic deletion of MYO1E aug-
ments LPS-induced chemokine (C-C motif) ligand 2
secretion in inflammatory cells [32]. The effects of CS on
the lungs of Myo1e−/−mice are unknown, but CS exposure
may enhance lung inflammation and possibly COPD in
Myo1e−/−mice.
We also identified three candidate genes (PLCH2,
KIAA1919, and MRPS34), which significantly augmented
cytotoxicity by siRNA knockdown alone. PLCH2 is a
member of the phospholipase C superfamily of enzymes
that regulate phosphoinositide turnover. Plch2−/− mice
exhibit no obvious phenotype. However, effects on lung
development have not been investigated [33]. KIAA1919
and MRPS34 encode a sodium-dependent glucose trans-
porter [34] and mitochondrial ribosomal protein S34
[35], respectively. Future studies will be needed to deter-
mine whether these genes are involved in the develop-
ment of respiratory systems using in vivo animal models.
Our in vitro siRNA screening further revealed a candi-
date gene whose knockdown protected against CSE-
induced cytotoxicity (SLC7A1). SLC7A1 was initially
selected from the VAAST analysis of susceptible smokers.
Since most rare disease-causing variants represent loss-of-
function mutations, and SLC7A1 was identified in suscep-
tible smokers, we might expect knockdown of this gene to
augment CSE-induced cytotoxicity. However, the opposite
effect was observed in the siRNA screening. It may be that
the specific mutations identified by the VAAST analysis
were rare gain-of-function mutations. Further experi-
ments examining the precise mutations are needed.
There are several limitations of this siRNA screening
approach, including inability to model gain-of-function
mutations or to assess epistasis, possible off-target
effects, and considerable variability among the individual
siRNA effects on gene silencing (e.g., 2 vs. 20 % of the
scrambled control). Further studies using primary mur-
ine tracheobronchial cells are required to validate our
in vitro findings. There are also other limitations when
using a simplistic siRNA/cell viability assay to assess
candidate genes. For example, inflammatory and endo-
thelial cells were not evaluated, though both are import-
ant in disease progression [36, 37]. A number of genes
are known to have high expression in inflammatory cells,
such as alveolar macrophages and pulmonary endothelial
cells, but not in airway epithelial cells [38, 39]. Based on
our requirement that genes be expressed in HBECs, we
may have excluded genes that may be important in
COPD through mechanisms involving inflammatory
cells. In future studies, we will include candidate genes
expressed in inflammatory cells, such as alveolar macro-
phages or lymphocytes. Also note that knocking down
genes is a rather blunt method. Recapitulating precise
mutations of interest using genome-editing technologies,
followed by in vitro functional studies, is likely much
more precise and a future goal of ours.
Conclusions
In this study, we identified candidate COPD genes
that augment spontaneous or CSE-induced cytotox-
icity through genomic, transcriptomic analyses, and
in vitro siRNA screening. In the future, we will deter-
mine the effects of candidate gene deletion on the
development of spontaneous and/or CS-induced
COPD in animal models.
Methods
Study subjects
Samples were collected from a cross-sectional case-
control study design, with no therapeutic intervention or
longitudinal follow-up information. All research involving
human subjects was approved by the authors’ institutional
review board (University of Iowa, New Mexico VA
Healthcare System (NMVAHCS), Lovelace Respiratory
Research Institute (LRRI) protocols: #200612711, e#11-
631, and #20031684, respectively). Informed consent was
obtained from all study subjects. Blood or whole lung tis-
sue samples were obtained from very advanced COPD
patients (n = 62) and resistant smokers (n = 30) enrolled in
the University of Iowa, NMVAHCS, LRRI, or the Lung
Tissue Research Consortium (LTRC). Advanced stage
COPD was defined as stages 3 or 4 COPD using the
GOLD executive summary 2007 (forced expiratory
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volume in 1 s [FEV1]/forced vital capacity [FVC] <0.70
and percentage of predicted FEV1 <50) [40], except for
three smokers who have more than 50 % predicted FEV1
but very low percentage of predicted diffusing capacity for
carbon monoxide (DLCO) (<30). We define exceptionally
resistant smokers as individuals who smoke at least 35
pack years, are >60 years of age, have normal spirometries,
and absence of significant comorbidities, such as non-
dermal malignancy or coronary artery disease. All study
subjects were of self-reported non-Hispanic white ethni-
city. We have excluded subjects with severe lung inflam-
mation due to chronic infection, immunosuppression due
to HIV infection, and known genetic diseases involving
the lung (such as cystic fibrosis or A1ATD).
DNA extraction
DNA extraction was performed using the QIAamp
Gentra Puregene Blood and Tissue kit according to
manufacturer’s instructions (Qiagen, Hilden, Germany).
For isolation of DNA from lung tissues, cell lysis solu-
tion was added to 50 mg of minced lung tissues and
then followed by addition of proteinase K and incubated
for 3 h at 55 °C. For isolation of DNA from blood sam-
ples, 10 mL of whole blood was resuspended in Pure-
gene Red Blood Cell Lysis Solution to lyse red blood
cells; this was followed by incubation at room
temperature for 5 min. Cell lysis solution was added to
the white blood cell pellet and vortexed vigorously for
10 s. To the completely digested tissue and blood lysates,
we added RNase A solution and protein precipitation
solution according to manufacturer’s instructions. The
supernatant from the previous step was added to a tube
containing isopropanol and mixed by inverting gently 50
times; 70 % ethanol was added and inverted several
times to wash the DNA. After final centrifugation and
removal of supernatant, the tubes were air-dried to
remove residual ethanol for 5–10 min. DNA hydration
solution was added and vortexed for 5 s and followed by
incubation at 65 °C for 1 h to dissolve the DNA. Concen-
tration and purity of the collected DNA were determined
using the NanoDrop ND-1000 spectrophotometer.
Whole exome data acquisition, processing, and variant
discovery
The whole exome sequencing library was constructed
using the SureSelectXT Human All Exon V4+UTRs kit
(Agilent, Santa Clara, CA) and sequenced using an Illu-
mina HiSeq 2000 system. The sequencing was performed
to achieve high-quality variant identification: overall ~60
million reads were sequenced for each individual, and an
average read depth of at least 50× was achieved for all
samples.
The variant discovery followed the Genome Analysis
Toolkit (GATK) Best Practices recommendations [41].
Briefly, raw sequences were aligned to the human refer-
ence genome (version hg 19) using Burrows-Wheeler
Aligner (BWA) [42]. The resulting raw alignments (in
binary sequence alignment/map format) were processed
by Picard (http://broadinstitute.github.io/picard) to re-
move PCR duplicates, followed by local realignment
around indels and base quality score recalibration using
GATK IndelRealigner and BaseRecalibrator respectively
[43]. Variant discovery was performed using GATK Uni-
fiedGenotyper using the joint calling function on all
samples. Raw variants quality scored were recalibrated
using GATK VariantRecalibrator and ApplyRecalibration
was used to generate a Variant Quality Score logarithm
of odds (VQSLOD). Finally, variants were filtered using
the following criteria: (1) VQSLOD ≥2 and (2) read
depth (DP) ≥6 in at least 80 % of samples. In addition,
any individual genotype with DP < 6 or GQ < 30 was
considered a no-call in the final dataset. The final data-
set along with annotation by ANNOVAR [44] are avail-




The variant data were analyzed using the Variant Anno-
tation, Analysis, and Search Tool (VAAST 2.0) package
[18]. The variants were annotated for their functional
impact using Variant Annotation Tool (VAT) in the
VAAST package. Then annotated variants in all suscep-
tible individuals and all resistant individuals were com-
bined into two condenser files using Variant Selection
Tool (VST). The susceptible and resistant condenser
files were analyzed using VAAST to prioritize candidate
genes under both dominant and recessive modes of
inheritance, allowing locus heterogeneity. We performed
the analysis either assuming complete penetrance of a
variant or allowing 5 % prevalence of a variant in the
control population. Complete penetrance means that no
individual in the background population can carry a
certain disease-causing variant, while allowing 5 %
prevalence means we estimate the expected disease allele
frequency within the background population to be 5 %
or lower.
The background population used for the analysis of
COPD samples were composed of variants from the 10
Gen dataset [45], 1057 genomes from the 1000 Genome
Project Phase I [46], 184 Danish exomes [47], 54 whole
genomes from the Complete Genomics Diversity Panel
[48], and resistant smoker sample exomes. The back-
ground files used for resistant smoker analysis are com-
posed of all the genomes or exomes mentioned above
(except the resistant smoker sample exomes) and COPD
susceptible sample exomes. We did not include 6500
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NHLBI exomes in the COPD sample background
because COPD subjects are present in this data set [12].
VAAST candidate-gene prioritization was performed
and variants in each gene were scored as a group. A rank
list of candidate genes was generated based on their
disease-causing probability. The significance level was
assessed with individual permutation tests. VAAST ana-
lysis parameters used: “-m lrt -lh y –significance 1e-4 -d
1e5 [-r 0.05|-pnt c] -iht [d|r]”.
Gene functional deficit score-based TTest and FCBF analysis
For the 92 individuals in our cohort, we extracted the set
of ANNOVAR annotated exonic variants [44]. We
mapped the RefSeq messenger RNA (mRNA) IDs identi-
fied by ANNOVAR to UniProt proteins. If a variant
mapped to different RefSeq IDs, all affected UniProt IDs
were included into the affected set. However, for each
variant only the primary isoform of the protein was con-
sidered. For each non-synonymous variant, we computed
the raw SNAP (screening for non-acceptable polymor-
phisms) score (range −100 to 100, any score ≥0 is classi-
fied as neutral/no functional change, and non-neutral
otherwise) [49]. For each gene in every individual, we
computed a gene functional deficit score as a sum over all
gene-specific variant scores. An individual variant score
was computed for each: (1) InDel or Stop loss/gain, score
= 1, (2) SNAP identified non-neutral non-synonymous
variant, score = SNAP score/100, (3) SNAP identified neu-
tral variant score = 0.055, and (4) synonymous variant,
score = 0.05. Further, individual variant scores of heterozy-
gous variants were multiplied by a factor of 0.25 to
approximately modulate the effects of heterozygosity.
Gene scores computed in this fashion are 0 only for genes
that have no variants at all. However, further comparison
between gene scores for different genes is not possible,
as the score is highly dependent on gene length and
overall tolerance for variability (e.g., longer genes with
more variable regions will tend to score higher while
remaining relatively functional biochemically). Note
that higher gene scores of statistically significant genes
in resistant individuals in our study may indicate genes
relevant for a resistance phenotype. We compared the
distribution of gene scores for resistant smokers vs. the
COPD-affected individuals using the t test metric. We also
applied to the entire set of genes in leave one out cross-
validation (92-fold) the fast correlation-based filter solution
(FCBF) feature selection algorithm [50]. The symmetrical
uncertainty attribute set evaluation in leave one out
cross-validation (WEKA implementation [51], parame-
ters = weka.attributeSelection.SymmetricalUncertAttrib
uteSetEval -s “weka.attributeSelection.FCBFSearch -D
false -T −1.7976931348623157E308 -N −1”) was also
combined to select a set of genes responsible for the
observed phenotype as a group, as opposed to a set
of genes individually contributing to the phenotype.
The feature set evaluation algorithm [50] evaluates
the worth of a set of attributes by measuring its sym-
metrical uncertainty with respect to another set of
attributes. Performance of a particular attribute set
was measured here by training J48 tree classifier [52]
(parameters: weka.classifiers.meta.AttributeSelectedClas-
sifier -E “weka.attributeSelection.SymmetricalUncertAttri-
buteSetEval ” -S “weka.attributeSelection.FCBFSearch -D
false -T −1.7976931348623157E308 -N −1” -W weka.clas-
sifiers.trees.J48 – -C 0.25 -M 2).
Sanger sequencing validation of variant calls
Sanger sequencing was used to validate the seven variants
in TACC2 genes found from the WES. Primer pairs used
to amplify PCR products harboring individual variants
were designed using Primer3 (http://biotools.umass
med.edu/bioapps/primer3_www.cgi). The detail informa-
tion of primers used for sequencing, including the
sequences, PCR product sizes, and annealing tempera-
tures, are listed (Additional file 7: Table S1). PCR with
those primer pairs was performed in 25-μl reaction with
OneTaq DNA polymerase (New England Biolabs, Ipswich,
MA). Half of the amount of each reaction was used for gel
electrophoresis to confirm the presence of a single ampli-
con with the expected fragment size. After the confirm-
ation, the remaining PCR product was purified by using
Illustra ExoProStar according to the manufacturer’s proto-
col (GE Healthcare Life Sciences, Buckinghamshire, UK).
The purified PCR products were then used for Sanger se-
quencing (GenScript, Piscataway, NJ).
Cell culture
Primary HBECs (pHBECs) from human lung tissues
were isolated from five nonsmoking donors and were
cultured in conventional systems under a protocol
approved by the LRRI Institutional Review Board as pre-
viously described [53]. HBEC2 cells (immortalized
HBECs) were originally generated by Ramirez, et al. [54]
and maintained as previously described [55]. Experi-
ments were performed in 12-well Costar tissue culture
plates at a starting cell density of 15 × 103/cm2. Cell
counts were performed by an electric particle counter
(Beckman Coulter, Indianapolis, IN).
Preparation of cigarette smoke extract (CSE)
One hundred millimeter research cigarettes (3R4F) were
purchased from the University of Kentucky. CSE were
prepared as previously described [56].
RNA-Seq
Total RNA was extracted using trizol from pHBEC cul-
tures of five non-smokers without COPD as previously
described [53]. Sequence libraries were constructed
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using the Illumina TruSeq RNA prep kit (San Diego,
CA). Multiplex sequencing was performed using the
Illumina HiSeq 2000 system. We generated between 30
and 35 million 2 × 50 pair-end reads per sample. The
raw sequences were aligned to the NCBI human genome
reference build 37 using BWA, and the expression level
of each transcript was determined using Tophat [57].
Gene expressions of approximately 32,500 gene tran-
scripts, including multiple transcript variants, were ana-
lyzed (as the fragments per kilobase of transcript per
million mapped reads (FPKM)). In total, 96.2 % of the
gene transcripts have less than tenfold variability (the
interquartile range of log10 expression equal to or less
than 1.0). To control the quality of our computation of
interquartile range, we have excluded all gene transcripts
with 2 or more zero FPKM values among the five
subjects.
Cell viability
Cell viability was determined by measuring the reduction
of 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) as previously described [55]. The MTT
absorbance was read at 570 nm.
RNA interference
Small interfering RNA (siRNA) for selected genes and
the scrambled (control) siRNA were purchased from Ap-
plied Biosystems (Carlsbad, CA). Transfection of siRNA
was performed using INTERFERin (Polyplus-tranfection
Inc, New York, NY) according to the manufacturer’s
instructions. The targeted sequences for the selected
genes are available (Additional file 8: Table S2). Twenty-
four hours after plating, cells were transfected with the
individual siRNA or the scrambled control for 48 h. The
transfected cells were exposed to 2 % CSE for 24 h in
the absence or presence of CSE as determined by the
MTT assay.
Flow cytometry
To detect apoptosis, flow cytometry using Annexin V-
FITC (BD Biosciences, Franklin Lakes, NJ) and propi-
dium iodide (Sigma, St Louis, MO) was performed as
previously described [58]. Early or late apoptosis was
defined by Annexin V+/PI– or Annexin V+/PI+ stain-
ing, respectively.
Immunoblotting
Immunoblot analysis was performed for active caspase-3
as previously described [59]. Equivalent loading was veri-
fied by stripping the blot and reprobing with antibodies
to β-actin.
Statistical analysis
The MTT absorption values from triplicated samples per
group were averaged for the following four groups: (A)
CSE-unexposed scrambled control cells, (B) CSE-
exposed scrambled control cells, (C) CSE-unexposed
siRNA-transfected cells, and (D) CSE-exposed siRNA-
transfected cells. Every 2–10 genes per independent
experiment were tested by siRNA transfection with a
scrambled control. The interaction of CSE and siRNA
effects on cell viability is quantified by the multiplicative
interaction ratio of averaged MTT absorption values
([D/C] divided by [B/A]). This ratio is expected to be
low or high if the targeted gene is protective or permis-
sive for CSE-induced cytotoxicity. The mean and robust
estimate of the standard deviation (nonparametric
pseudo SD = interquartile range divided by 1.35) of these
interactions are used to compute a Z-score. A one-side
p value for each gene (by one-sample Z-test) was applied
to detect both tails of genes. The effects of siRNA alone
were also quantified by the ratio of C/A and further ana-
lyzed to detect other candidate genes among the 45 genes,
whose siRNA reduced the MTT value compared with the
scrambled control. The Benjamini and Hochberg (BH)
false discovery rate (FDR) procedure is applied to the
sorted list of p values (smallest to largest) using the for-
mula BH (j) = αj/n, where α = 0.05 and j is the index num-
ber of the list of p values and n is the total number of
candidate genes. The p values, p (j), and the correspond-
ing genes are considered significant for all genes whose p
(j) ≤ BH (j).
Additional files
Additional file 1: COPD candidate genes prioritized by the VAAST
analysis. Results from different VAAST run settings (Table 1) are shown in
seperated tabs. The tab list and the column definition are shown in the
tab "TableList". (XLSX 665 kb)
Additional file 2: COPD candidate genes prioritized by the Gene
Functional Deficit Score-based TTest and FCBF Analysis.
Results from Gene Functional Deficit Score-based t test, FCBF analysis, and
induced network modules analysis are shown in different tabs. (XLSX 384
kb)
Additional file 3: The abundance of gene expression in primary
human epithelial cell cultures using RNA-Seq. Expression level (FPKM)
of 32,457 transcripts from five nonsmoking donors and the average
expression level are shown. (XLSX 4.16 mb)
Additional file 4: siRNA screening in vitro analysis for 81 COPD
candidate genes. For the 81 candidate genes, the detailed gene
information, selection method, and annotation are shown in the tab
"Gene Selection Methods". The siRNA knockdown results in three trials
are shown in the tab "siRNA summary". (XLSX 92.6 kb)
Additional file 5: Annotated variants for the 81 COPD candidate
genes. Whole exome sequencing variants identified in the 81 COPD
candidate genes in the 62 susceptible smokers with COPD (tab
"Susceptible") and 30 resistant smokers (tab "Resistant"). The variant list is
in VCF format and annotated with ANNOVAR, except the first column
which lists the gene id. (XLSX 1.23 mb)
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Additional file 6: Gene Ontology term enrichment analysis on the
81 candidate genes. (XLSX 19.0 kb)
Additional file 7: Table S1. The information of Sanger sequencing
validation for seven exonic variants of TACC2. (DOCX 13.8 kb)
Additional file 8: Table S2. Table S2 siRNA sequences targeting 81
COPD candidate genes. (DOCX 28.9 kb)
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